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Summary.-Assays for the capacity of peripheral-blood monocytes (a) to mature
in vitro into macrophages, (b) to reduce nitro-blue tetrazolium (NBT) and (c) to lyse
antibody-coated human Group A red cells, were applied to a group of82 patients with
histologically proven malignant melanoma. In patients with micrometastatic disease
there was an enhancement of red-cell lysis and NBT reduction, suggesting that their
monocytes are in some way "activated", whereas NBT reduction was suppressed in
those with overt dissemination. Monocyte maturation in vitro was impaired in all
patient groups to an extent which correlated with overall tumour burden.
Corynebacterium parvum was administered i.v. to 12 patients with disseminated
disease and by the intradermal route to24 patients with micrometastatic disease. The
3 monocyte functions were significantly enhanced by C. parvum.
THERE IS INCREASING EVIDENCE from
animal studies that the mononuclear
phagocyte system (MPS) may play an
important effector role in host responses
to malignant tumours (Alexander, 1976)
and that the administration of Corynebac-
teriunt parvium can exert anti-tumour
activity by inducing proliferation and
activation ofcells in the MPS (Scott, 1974).
Monocyte function in patients with malig-
nant melanoma is disturbed. Using assays
designed to examine 3 different aspects of
monocyte function (differentiation, NBT
reduction and lysis of opsonized erythro-
cytes) we have previously obtained evi-
dence (Currie & Hedley, 1977; Hedley &
Currie, 1978) that the detectable abnor-
malities may be related to clinical tumour
burden. In brief, these earlier studies
showed that, in patients with minimal
tumour burden, peripheral blood mono-
cytes, although showing defective differ-
entiation, are "activated" relative to age-
matched control donors, and that these
monocyte functions become depressed in
patients with overt disseminated disease.
We now report a more detailed examina-
tion of a larger series of patients which
firmly establishes correlations between
clinical tumour burden and certain mono-
cyte functions. We have also examined
the effects of administration of C. parvum
to selected subgroups of patients to
determine whether this agent can enhance
the functions of peripheral-blood mono-
cytes, and to examine the effect of its
route, dosage and timing of administra-
tion, in order to design an optimally
effective, minimally toxic regimen for
subsequent clinical evaluation.
MATERIALS AND METHODS
Patients
A total of 82 patients attending the melan-
oma clinic at this hospital were investigated.
Blood samples were taken before the adminis-
tration ofany systemic treatment. No patient
wvas investigated within 3 weeks of prior
surgery.
These patients as a group were a highly
selected population in that they all had re-
ceived prior surgery. Forty-five patients had
clinically overt disseminated disease. The
remaining 37 were those with an undetectable
tumour burden following surgery, but with a
poor prognosis. They comprised patients withMONOCYTES, MACROPHAGES AND MELANOMA
deeply penetrating primary tumours (Clark's
Levels IV and V), surgically treated Stage
IIB disease or surgically treated recurrent
local or distant cutaneous disease. We refer to
the disease in these patients as "micrometa-
static". An unknown but small number were
probably cured by the surgery and did not
have micrometastatic disease, but since we
are unable to identify them they cannot be
excluded from these investigations. Details
of the groups of patients receiving C. parvumn
will be given below. Normal control blood
samples were obtained from a group of 48
heterogeneous normal donors. They were not
rigorously age-matched since we have been
unable to detect any effect of age on mono-
cyte funietion in panels of normal donors.
Assays of monocyte function
Mononuclear-cell suspensions w%!ere pre-
pared from defibrinated peripheral venous
blood using the method ofBoyum (1968), and
examined by enzyme cytochemistry (Yam et
al., 1971). The percentage of cells staining
diffusely for the monocyte marker non-
specific esterase (NSE) was estimated and,
because of the possibility of errors in the
monocyte-function assays due to contamin-
ating granulocytes, the latter cells were also
counted using chloroacetate-esterase activity
as a marker.
Monocyte maturation.-In brief, this
method examines the ability of monocytes to
mature into macrophages when cultured in
500 ° fresh autologous serum at 37°C for 7
days in the wells of 3040 (Falcon Plastics)
microplates (Currie & Hedley, 1977). The
macrophage nuclei were detached and stained
using a solution of0-IM citric acid plus 1: 2000
crystal violet, and counted in a haemacyto-
meter. Results were expressed as the percent-
age ofNSE+ cells maturing into macrophages.
Monocyte NBT reduction. The capacity of
monocytes to reduce the dye nitro-blue
tetrazolium was measured by a quantitative
assay (Hedley & Currie, 1978). The rate of
dye reduction is an indirect measure of
hexose-monophosphate-shunt activity, the
enhancement of which is associated with
monocyte "activation".
Mononuclear cells were pre-incubated for
15 min in the presence of latex polystyrene
particles, which acted as a phagocytic
stimulus, after which a solution of NBT was
added.
After 60 min incubation with NBT the
reaction was stopped by acidifying the mix-
ture, the cells were washed and then reduced,
insoluble NBT was extracted into dioxan at
70°C. Optical density at 520 nm was measured
and, by reference to a standardization curve,
the amount of NBT reduced per NSE+ cell,
both resting and after latex preincubation,
could be calculated.
Lysis of antibody-coated enthrocytes.-The
ability of peripheral-blood monocyte to lyse
antibody-coated human erythrocytes was
measured using the method of Nyholm &
Currie (1978). Fresh human Group A red cells
were labelled with sodium (51Cr)chromate,
trypsinized and coated with a hyperimmune
anti-A1 serum. Fifty microlitres of Medium
199 containing 105 red cells were added to the
wells of 3040 plates (Falcon Plastics) contain-
ing serial dilutions of mononuclear cells
ranging from 1 0 to 5 0x 105 in 50 Iul. The
plates were incubated at 37°C for 2 h and the
release of 51Cr counted in an automatic
gamma counter. The results were then ex-
pressed as a percentage of 51Cr release deter-
mined as follows:
Release in test well
00O 5 1 Cr r ela-spontaneous release
Total releasable
-spontaneous release
The total releasable 51Cr was measuIred
after the addition of 500 sodium dodecyl
sulphate.
A parameter wAas then derived describing
the number of red cells lysed per NSE+ cell.
Administration of C. parvumn
C. parvum (Coparvax. The Wellcome
Foundation Limited), was administered to 2
groups of patients. A group of 12 patients
with overt disseminated disease was given
C. parvum by the i.v. route. A range of start-
ing doses from 700 ,ug to 7 mg were infused
i.v. diluted in 200 ml dextrose-saline over a
period of 30 min. The patients were closely
observed for the next 48 h. Blood samples for
routine haematological and biochemical in-
vestigations were taken at frequent intervals,
and monocyte-function tests performed be-
fore infusion and at intervals thereafter. No
other medication was given unless indicated
by symptoms.
A further series of 24 patients with 'micro-
metastatic" disease were given C. parvum by
the intradermal (i.d.) route. The vaccine was
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diluted in sterile physiological saline to a
final concentration of 700 ,ug/ml and was
given by i.d. injection in Olml volumes into
the deltoid region (of an arm uninvolved by
tumour) in doses ranging from 70 jug to
560 jug at intervals (2, 3, or 4 weeks) for a
total period of 6 months. These 24 patients
were a heterogeneous group, including 16
with surgically treated Stage IIB disease, 3
with level IV or V primary tumours, 3 with
recurrent primary tumours, 1 rectal primary
and 1 with a single distant cutaneous meta-
stasis.
RESULTS
Monocyte function and tumour burden
Monocyte maturation.-Data obtained
from 82 patients and 30 normal donors
expressed as percent maturation, are
shown in Table I and Fig. 1. The patients,
after conventional clinical staging, were
divided into those with "micrometastatic"
disease and those with overt disseminated
disease. The patients in the latter category
were further subdivided into those whose
disease was apparently confined to skin,
lymph nodes and/or lungs and those where
disease involved liver, brain, bone or
viscera. As can be seen from the data there
are statistically significant differences be-
tween each of the groups (i.e. monocyte
maturation in normal donors>micro-
metastatic disease>disseminated disease).
Furthermore, in the latter group, those
with disease in skin lymph node and/or
lung show significantly higher values than
those with visceral, brain or bone disease.
Quantitative NBT reduction.-The data
obtained in 48 normal donors and 60
patients with malignant melanoma are
seen in Table I. In 34 patients with micro-
metastatic disease the resting NBT reduc-
tion was 12 4+5 3 (s.d.)x 10-15 mol/
NSE+ cell, whereas in the normal donors
the value obtained was 10 4 x 3 3. This
difference became more apparent after
latex stimulation (normals 15'2±4 9 x
10-15 mol/NSE+ cell, micrometastatic
disease 18-0±6-3; P<0 05). Furthermore,
the patients with overt disseminated
disease showed significantly depressed
NBT reduction (89±4-1 x 10-15 mol/
NSE+ cell) which responded poorly to
stimulation by latex particles (116±3.9
x 10-15 mol/NSE+ cell). Again, patients
with visceral metastases showed the most
severe defect.
Lysis of antibody-coated erythrocytes.-
The results of this assay were used to
derive a parameter describing the number
of antibody-coated Group A red cells
TABLEI.-Correlationsofclinicaltumourstagewithresultsfrom 3assaysofmonocytefunction
Maturation %
Resting NBT:
Reductionfmol/monocyte
Stimulated NBT:
Reduction fmol/monocyte
Red cells
lysed/monocyte
Mela
Micro- All
Normal metastatic disseminated
(n) (n) (n)
(30) (37) (45)
471 ±22-3 28-2+16-0 14-8±12-1
P<0-001 P<0-001
(48) (34) (26)
10-4±3-3 12-4±5-3 8-9±4-1
N.S. P<0-01
(48) (34) (26)
15-2±4-9 18-0±-6-3 11-9±3-9
P<0-05 P<0-001
(39) (32)
0-56±0-35 0-92±5-1
P<0.001 N.S.
inomas
-A
Skin, node,
or lung Visceral
metastases metastases
(n) (n)
(18) (27)
20-9±14-5 10-7±8-9
*1 P<0-02
*2
(13)
10-2 ±4-4
N.S.
(13)
13-4±3-6
*3 P<0-02
(13)
7-5±3-3
(13)
9-9±3-3
(23) (11) (12)
0 77±0-42 0-81±0-51 0-73±0-32
*4 N.S.
Pvalues are derivedfrom data inadjacent columns (except * whencomparison isnormal v. alldisseminated).
*1. P<0.001.
*2. N.S.
*3. P<0-001.
*4. P<0 05.
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FIG. 1. Percentage of monocytes maturing
into macrophages according to disease
stage.
lysed per monocyte (defined as NSE+
cells). The assay was performed on 39
normal donors who provided a mean
value of 0'56±0 35 red cells/monocyte,
whereas 32 patients with micrometastatic
disease gave a mean of 0'92L0-51 red
cells/monocyte, a difference which is
highly significant (P<0-001) and indicates
that monocytes from such patients show
increased lytic- activity. In a smaller
group of 23 patients with disseminated
disease the mean value was 0 7740'42 red
cells/monocyte, a figure significantly
higher than that from the normal donors
(P<0 05) (Table I).
Effects of C. parvum
Hazards of i.v. administration.-When
given by this route in doses ranging from
700 jig to 7 mg the toxic side effects com-
prised fever, chills, nausea, rigors, head-
ache, tachycardia, transient hypertension
or hypotension: a syndrome described by
the patients as like severe influenza, and
which persisted for 2-3 days. One patient
collapsed and died 16 h after an i.v. in-
fusion of C. parvum, and we therefore did
not feel justified in continuing to use this
agent by the i.v. route. This patient, a
man aged 41 with widespread pulmonary
metastases, was treated according to a
protocol comprising alternating C. parvum
and chemotherapy (DTIC and vincristine)
at 2-week intervals. About 16 h after his
second i.v. infusion of 7 mg C. parvum he
collapsed and died. Subsequent post-
mortem examination showed no evidence
of cardiovascular disease or intravascular
coagulation, and confirmed the presence
of extensive lung deposits of malignant
melanoma. The immediate cause of his
death remains unexplained.
Since the i.v. route was abandoned on
the grounds of toxicity, the data obtained
from studies of monocyte-function were
limited. However, results from the mono-
cyte maturation assay performed before
and 7-14 days after the first infusion of
C. parvum showed substantial (and sig-
nificant) increases in monocyte matura-
tion which was not related to the dose of
C. parvum (i.e. patients given 700 pg pro-
vided results similar to those receiving
7 mg; data not shown).
Intradermal administration.-When
given by this route C. parvum was without
toxicity. At the local injection site there
were mild indurated erythematous reac-
tions, resembling delayed-type hyper-
sensitivity. These were never severe, and
never led to ulceration, scarring or abscess
formation. There was no symptomatic,
haematological or biochemical evidence of
systemic toxicity.
A total of 24 patients were given C.
parvum by the i.d. route and in vitro data
were obtained on 21. The monocyte-
function assays were performed before the
first injection and at intervals thereafter.
The detailed results are shown in Table II,
which describes the effects on monocyte
function after the first i.d. injection of
C. parvum in these 21 patients. In general,
C. parvum i.d. caused a significant eleva-
561
IAA-
00
0 9
0 00
0
0
0
:0
V
:0
00
:0
0 0 0 0: 0 00
XD. W. HEDLEY, R. E. NYHOLM AND G. A. CURRIE
-, F
0
01
ml; -00tu t0z0 00
0
0 r
o1t
<00
0 a0
z~~~~~~~~~~~~~~~~~~~~ aq -
02 v
_)
- t --4 cq-- -- - - _ -
0 --
C).
0 X
t ~)0 55 _
- - - - - - - - -I 4 -I ~ - ~ *
t3 ~ ~ ~ ~~~~- 0 e-O " ^
_ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~D Co . . . .. . .. .
0 4-- t- o1 _0 jt_to C O t- (M _q o0 0esooCD0
= - a toc> t1 >-m -o _ X c W- N -
< H~~~~~-1
O a) >C if C OOO O OCOO CO CO COCO O CO
562MONOCYTES, MACROPHAGES AND MELANOMA
tion in the functions assayed. Using the
Wilcoxon test for matched pairs, the
injection ofC. parvum caused a significant
rise in monocyte maturation (P<0.05), a
rise in unstimulated NBT reduction
(P<0*01) and a rise in stimulated NBT
reduction (P<0.01). The assay for lysis of
opsonized erythrocytes also showed a sig-
nificant increase (P<0.01).
A range of doses from 105 ,ug to 560 ,ug
revealed no clear dose relationship in
effects of any of the assays. Continued i.d.
injections of C. parvum (at 2-, 3- or 4-
weekly intervals) led to complex patterns
ofrise and fall of the assays. In 4 patients
(1 after the first injection, the other 3 after
multiple injections) the monocyte-matura-
tion assay provided values well over 100%.
In other words, proliferation of cells was
occurring in vitro. Mitotic figures were
seen in these cultures, a phenomenon
never seen in cultures from untreated
patients or normal donors. We interpret
this finding as evidence for a population
of circulating progenitor cells evoked by
the C. parvum.
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FIG. 2. Monocyte maturation in 6 patients
with micrometastatic melanoma and re-
ceiving repeated intradermal C. parvum
(as arrowed) : * *remaining disease-
free; 0-- OR, early relapse.
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FIG. 3. Monocyte NBT reduction (10-15
fmol/NSE+ cell) in patients with micro-
metastatic melanoma and receiving re-
peated intradermal C. parvum (as arrowed)
0--S remaining disease-free; O OR,
early relapse.
Since the start ofthis study (16 months)
3 patients in this micrometastatic group
receiving i.d. C. parvum have relapsed
with metastatic disease. The results of
their monocyte functions are shown in
Figs 2 and 3, and are compared to those
of 3 clinically similar patients who have
not so far shown any evidence ofrecurrent
disease. Monocyte maturation and NBT
reduction in these 3 early-relapse patients
show a small transient rise followed by a
fall coincident with (or in 2 cases pre-
ceding) clinically detectable recurrence.
The patients not relapsing showed a
greater response to C. parvum, which was
sustained for much longer (3-4 months).
However, even in these cases (with no sign
of relapse) receiving periodic C. parvum
injections, the responses (both maturation
and NBT reduction) eventually subsided
towards normal levels after 3-4 months.
DISCUSSION
Monocyte functions and clinical stage
Since Dizon & Southam's (1963) demon-
stration ofdefective macrophage mobiliza-
tion in malignant disease, many attempts
have been made to examine cells of the
MPS in such patients. A variety of func-
tional abnormalities of peripheral-blood
monocytes have been described, including
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increased hexose-monophosphate-shunt
activity (King et al., 1977), increased ex-
pression of Fc receptors (Lobuglio, 1970;
Rhodes, 1977) and defective chemotaxis
(Boetcher & Leonard, 1974). Our own
studies have been concerned with three
assays for various aspects of monocyte
function, and include maturation in vitro
into macrophages, quantitative reduction
of nitro-blue tetrazolium (NBT) and the
capacity to lyse antibody-coated human
erythrocytes. The results indicate that the
capacity of monocytes to mature in vitro
clearly correlates with disease burden.
Patients with disease disseminated to
viscera, bone or brain, and therefore with
the worst prognosis (Luce, 1972; Einhorn
et al., 1974), show the lowest % matura-
tion. Those with micrometastatic disease
(i.e. clinically disease-free but with a very
high risk of recurrence) provide much
higher values, which are still significantly
less than the control donor values. There
was no correlation between suppression of
monocyte maturation and the presence of
granulocytes or other contaminant cells in
the mononuclear-cell suspensions. Pre-
liminary results indicate that suppression
ofmonocyte differentiation is mediated by
labile factor(s) in the patient's sera. NBT
reduction, however, shows a more complex
pattern. Monocytes from patients with
disseminated disease show depressed rest-
ing NBT reduction and a deficient capa-
city to respond to a phagocytic stimulus.
However, patients with micrometastatic
disease provided values for resting NBT
reduction above the normal donor values,
and after a phagocyte stimulus showed a
hypernormal response. We interpret this
as evidence for some form of as yet un-
characterized activation. This observation
is supported by the earlier work of King
et al. (1977) and by the data from the
erythrocyte-lysis assay. Rhodes (1977) has
reported the increased expression of Fc
receptors on the monocytes from cancer
patients, perhaps another aspect of
"activation". These findings all suggest
an important role for the MPS in host
responses to a malignant tumour.
Effects ofC. parvum
Manipulation of the MPS constitutes
one of the major (and as yet unsuccessful)
approaches to the immunotherapy of
human cancer (Terry & Windhorst, 1978).
Corynebacterium parvum has been given
to patients with a variety of diseases by
various routes in a range of doses. The
ability of C. parvum to modify functions
of the MPS in man has been hinted at by
studies of the clearance of 1251-labelled
aggregated albumin (Attie, 1975) and the
development of a monocytosis (Israel,
1975). Our own studies were performed in
order to determine the optimal (and
safest) mode of administering C. parvum
(i.e. route, dose and timing). C. parvum
injected i.v. produced unacceptably toxic
side effects. When given i.d., however, it
was without adverse effects and raised all
3 monocyte functions examined: matura-
tion, NBT reduction and lytic capacity.
There was no obvious influence of dose:
105 tg produced changes similar to those
at much higher doses. Repeated adminis-
tration at 2- or 3-week intervals led to a
progressive rise in the monocyte functions
in most of the patients. There was a
suggestion from these data that 2- or
3-week intervals provide a better long-
term stimulating effect on monocyte
function than intervals of 4 weeks. In 4
patients given i.d. C. parvum there was
evidence of in vitro proliferation of mono-
cytes, as shown by the presence of mitotic
figuresinthe culturesandeventual matura-
tion indices in excess of 100%. This
observation is reminiscent of the known
effects of C. parvum on marrow colony-
forming cells (Wolmark & Fisher, 1974).
We have never encountered this pheno-
menon in the patients or normal donors
not receiving C. parvum. Three of the
patients showed only minor and transient
responses to C.parvurn followed byrapidly
subsiding monocyte function. Each of
these 3 relapsed early with overt dis-
seminated disease, the collapse of mono-
cyte functions preceding clinical detection
of metastatic disease.
Since the i.d. administration of C.
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parvum every 2-.3 weeks in doses around
100-400 /g can produce a series ofchanges
in monocyte f,unction interpretable as
stimulation and/or activation, such a
protocol is being evaluated as an adjuvant
form of therapy'.
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